

DAFTAR PUSTAKA

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics , 2009, *Ca-a Cancer Journal for Clinicians*,. 2009;59(4):225–49.
2. World Health Organization. Indonesia Source GLOBOCAN 2018. Int Agency Res Cancer [Internet]. 2019;256:1–2. Available from: <http://gco.iarc.fr/>
3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Engl J Med*. 2002;346(2):92–8.
4. Cohen S. The stimulation of epidermal proliferation by a specific protein (EGF). *Dev Biol*. 1965;12(3):394–407.
5. Mendelsohn J. Growth factor receptors as targets for antitumor therapy with monoclonal antibodies. *Prog Allergy*. 1988;45:147–60.
6. Malik PS, Jain D, Kumar L. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer. *Oncol*. 2016;91(1):26–34.
7. Nan X, Xie C, Yu X, et al. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. *Oncotarget*, 2017, 8(43): 75712-75726. doi: 10.18632/oncotarget.20095
8. Fujiwara, A., Yoshida, M., Fujimoto, H., Nakahara, H., Ito, K., Nishihama, K., Yasuma, T., Hataji, O., Taguchi, O., D’Alessandro-Gabazza, C., Gabazza, E. and Kobayashi, T., 2018. A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer. *Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics*, 26(7), pp.1031-1036.
9. Garcia-Cuevas, L., Alvarez, P., Comas, R., Clavo, S., Morera, D., Mangas, C., Lobato, E. and Mayoral, J., 2017. CP-051 Comparing the efficacy of afatinib versus erlotinib or gefitinib in non-small cell lung cancer patients. *Clinical pharmacy*,.
10. Noorwati SUTANDYO, Arif HANAFI, Mulawarman JAYUSMAN. Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population. *Zhongguo Fei Ai Za Zhi*, 2019, 22(9): 562-567. DOI: 10.3779/j.issn.1009-3419.2019.09.02
11. Murray. Bronchogenic carcinoma . Dalam: Mason R, ed. Murray and Nadel's Textbook Of Respiratory Medicine. 4th edition ed. Philadelphia: Elsevier Saunders; 2005.h.1357-82.
12. PDPI. Kanker paru (kanker paru jenis karsinoma bukan sel kecil) : Pedoman Diagnosis dan penatalaksanaan di Indonesia. PDPI. 2011: 1-35.

13. Jusuf A, Wibawanto A, Icksan A.G., dkk. Kanker Paru (Kanker Paru Jenis Karsinoma Bukan Sel Kecil). Pedoman Diagnosis dan Penatalaksanaan di Indonesia. PDPI 2018; 1 - 45.
14. Bach PB, Silvesri GA, Hanger M, Jett JR. Screening for Lung Cancer : ACCP evidence based clinical practice guidelines 2nd edition. Chest. 2007; 132:69S-77S.
15. Mollberg N, Surati M, Demchuk C, Fathi R, Salama AK, Husain AN, et al. Mind-mapping for lung cancer: Towards a personalized therapeutics approach. Adv Ther. 2011;28(3):173- 94.
16. Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer Cell. 2002;1(1):49–52.
17. Minna J. implications. 2003;892–901.
18. Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: An overview and update. J Thorac Dis. 2010;2(1):48–51.
19. Inamura K, Ninomiya H, Ishikawa Y, Matsubara O. Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? Arch Pathol Lab Med. 2010;134(1):66–72.
20. Ohsaki Y, Tanno S, Fujita Y, Toyoshima E, Fujiuchi S, Nishigaki Y, et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep. 2000;7(3):603–7.
21. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–37.
22. Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341–54.
23. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: A model for targeted therapy. Clin Cancer Res. 2006;12(18):5268–72.
24. Lowenstein EJ, Daly RJ, Batzer AG, Li W, Margolis B, Lammers R, et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell. 1992;70(3):431–42.
25. Batzer AG, Rotin D, Ureña JM, Skolnik EY, Schlessinger J. Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Biol. 1994;14(8):5192–201.
26. Hallberg B, Rayter SI, Downward J. Interaction of Ras and Raf in intact mammalian cells upon extracellular stimulation. J Biol Chem. 1994;269(6):3913–6.

27. Liebmann C. Regulation of MAP kinase activity by peptide receptor signalling pathway: Paradigms of multiplicity. *Cell Signal*. 2001;13(11):777–85.
28. Gaestel M. MAPKAP kinases - MKs - Two's company, three's a crowd. *Nat Rev Mol Cell Biol*. 2006;7(2):120–30.
29. Hill CS, Treisman R. Transcriptional Regulation by Extracellular signals: Mechanisms and Specificity. *Cell*. 1995;80(2):199–211.
30. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase-AKT pathway in humancancer. *Nat Rev Cancer*. 2002;2(7):489–501.
31. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. *Nature*. 2006;441(7092):424–30.
32. Carpenter CL, Auger KR, Chanudhuri M, Yoakim M, Schaffhausen B, Shoelson S, et al. Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. *J Biol Chem*. 1993;268(13):9478–83.
33. Mattoon DR, Lamothe B, Lax I, Schlessinger J. The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway. *BMC Biol*. 2004;2:1–12.
34. Patterson RL, Van Rossum DB, Nikolaidis N, Gill DL, Snyder SH. Phospholipase C- γ : Diverse roles in receptor-mediated calcium signaling. *Trends Biochem Sci*. 2005;30(12):688–97.
35. Chattopadhyay A, Vecchi M, Ji QS, Mernaugh R, Carpenter G. The role of individual SH2 domains in mediating association of phospholipase C- γ 1 with the activated EGF receptor. *J Biol Chem*. 1999;274(37):26091–7.
36. Schönwasser DC, Marais RM, Marshall CJ, Parker PJ. Activation of the Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Pathway by Conventional, Novel, and Atypical Protein Kinase C Isotypes. *Mol Cell Biol*. 1998;18(2):790–8.
37. McClellan M, Kievit P, Auersperg N, Rodland K. Regulation of proliferation and apoptosis by epidermal growth factor and protein kinase C in human ovarian surface epithelial cells. *Exp Cell Res*. 1999;246(2):471–9.
38. Haura EB, Turkson J, Jove R. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. *Nat Clin Pract Oncol*. 2005;2(6):315–24.
39. Bromberg J. JAK-STAT signaling in human disease Stat proteins and oncogenesis. *J Clin Invest*. 2002;109(9):1139–42.

40. Yeatman TJ. A renaissance for SRC. *Nat Rev Cancer*. 2004;4(6):470–80.
41. Summy JM, Gallick GE. Treatment for advanced tumors: Src reclaims center stage. *Clin Cancer Res*. 2006;12(5):1398–401.
42. Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan 70101, R.O.C. Institute of Biochemistry, Chung Shan Medical University, Taichung, Taiwan, R.O.C. 2003;28–38.
43. Jorissen RN, Walker F, Pouliot N, Garrett TPJ, Ward CW, Burgess AW. Epidermal growth factor receptor: Mechanisms of activation and signalling. *Exp Cell Res*. 2003;284(1):31–53.
44. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. Target-based agents against ErbB receptors and their ligands: A novel approach to cancer treatment. *Endocr Relat Cancer*. 2003;10(1):1–21.
45. Tanoue LT. EGFR Antagonists in Cancer Treatment. *Yearb Pulm Dis*. 2009;2009:177–9.
46. Normanno N, Pergameno M, Iannaccone A, De Luca A. Mechanisms of action of EGFR inhibitors. *EGFR Inhib Cancer Treat*. 2012;7–17.
47. Svensson LG, Ph D, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, et al. *New England Journal*. 2011;2187–98.
48. Malik PS, Jain D, Kumar L. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer. *Oncol*. 2016;91(1):26–34.
49. Sequist L V., Yang JCH, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. *J Clin Oncol*. 2013;31(27):3327–34.
50. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. *Lancet Oncol [Internet]*. 2014;15(2):213–22. Available from: [http://dx.doi.org/10.1016/S1470-2045\(13\)70604-1](http://dx.doi.org/10.1016/S1470-2045(13)70604-1)
51. Li J, Zhao M, He P, Hidalgo M, Baker SD. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. *Clin Cancer Res*. 2007;13(12):3731–7.
52. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. *Lancet Oncol [Internet]*.

2012;13(3):239–46. Available from: [http://dx.doi.org/10.1016/S1470-2045\(11\)70393-X](http://dx.doi.org/10.1016/S1470-2045(11)70393-X)

53. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. *J Clin Oncol*. 2001;19(13):3267–79.
54. Yamamoto N, Horiike A, Fujisaka Y, Murakami H, Shimoyama T, Yamada Y, et al. Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. *Cancer Chemother Pharmacol*. 2008;61(3):489–96.
55. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. *Oncogene*. 2008;27(34):4702–11.
56. Ling J, Johnson KA, Miao Z, Rakhit A, Pantze MP, Hamilton M, et al. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. *Drug Metab Dispos*. 2006;34(3):420–6.
57. Solassol I, Pinguet F, Quantin X. FDA- and EMA-approved tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer: Safety, tolerability, plasma concentration monitoring, and management. *Biomolecules*. 2019;9(11).
58. Kletzl H, Giraudon M, Ducray PS, Abt M, Hamilton M, Lum BL. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: Omeprazole and ranitidine. *Anticancer Drugs*. 2014;26(5):565–72.
59. Rossi RE, Massironi S, Conte D, Peracchi M. Therapy for metastatic pancreatic neuroendocrine tumors. *Ann Transl Med*. 2014;2(1):1–12.
60. Anderson NG, Ahmad T, Chan K, Dobson R, Bundred NJ. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. *Int J Cancer*. 2001;94(6):774–82.
61. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. *Clin Cancer Res*. 2001;7(5):1459–65.
62. Swaisland HC, Smith RP, Laight A, Kerr DJ, Ranson M, Wilder-Smith CH, et al. Single-dose clinical pharmacokinetic studies of gefitinib. *Clin Pharmacokinet*. 2005;44(11):1165–77.

63. Yasumuro O, Uchida S, Kashiwagura Y, Suzuki A, Tanaka S, Inui N, et al. Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats. *Xenobiotica* [Internet]. 2018;48(11):1106–12. Available from: <http://dx.doi.org/10.1080/00498254.2017.1396379>
64. McKillop D, Hutchison M, Partridge EA, Bushby N, Cooper CMF, Clarkson-Jones JA, et al. Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. *Xenobiotica*. 2004;34(10):917–34.
65. Keating GM. Afatinib: A review of its use in the treatment of advanced non-small cell lung cancer. *Drugs*. 2014;74(2):207–21.
66. Yang JCH, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials. *Lancet Oncol* [Internet]. 2015;16(2):141–51. Available from: [http://dx.doi.org/10.1016/S1470-2045\(14\)71173-8](http://dx.doi.org/10.1016/S1470-2045(14)71173-8)
67. Paz-Ares L, Tan EH, O'Byrne K, Zhang L, Hirsh V, Boyer M, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial. *Ann Oncol*. 2017;28(2):270–7.
68. Eskens FALM, Mom CH, Planting AST, Gietema JA, Amelsberg A, Huisman H, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. *Br J Cancer*. 2008;98(1):80–5.
69. Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. *J Clin Oncol*. 2010;28(25):3965–72.
70. Gunzer K, Joly F, Ferrero JM, Gligorov J, de Mont-Serrat H, Uttenreuther-Fischer M, et al. A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole. *Springerplus*. 2016;5(1):1–12.
71. Suder A, Ang JE, Kyle F, Harris D, Rudman S, Kristeleit R, et al. A phase I study of daily afatinib, an irreversible ERBB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours. *Eur J Cancer* [Internet]. 2015;51(16):2275–84. Available from: <http://dx.doi.org/10.1016/j.ejca.2015.07.041>
72. Wind S, Giessmann T, Jungnik A, Brand T, Marzin K, Bertulis J, et al. Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir. *Clin Drug Investig*. 2014;34(3):173–82.

73. PDPI. Kanker paru (kanker paru jenis karsinoma bukan sel kecil) : Pedoman Diagnosis dan Penatalaksanaan di Indonesia. PDPI. 2011: 1-35.
74. Grutters JPC, Joore MA, Wiegman EM, Langendijk JA, De Ruyscher D, Hochstenbag M, et al. Health-related quality of life in patients surviving non-small cell lung cancer. *Thorax*. 2010;65(10):903–7.
75. Hwang KE, Kim HR. Response evaluation of chemotherapy for lung cancer. *Tuberc Respir Dis (Seoul)*. 2017;80(2):136–42.
76. Nishino M, Jagannathan JP, Ramaiya NH, Van Den Abbeele AD. Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. *Am J Roentgenol*. 2010;195(2):281–9.
77. Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: An overview and update. *J Thorac Dis*. 2010;2(1):48–51.
78. Agency EM. Assessment Report for IRESSA. *React Wkly*. 2009;NA;(1282):86.
79. Fujiwara, A., Yoshida, M., Fujimoto, H., Nakahara, H., Ito, K., Nishihama, K., Yasuma, T., Hataji, O., Taguchi, O., D’Alessandro-Gabazza, C., Gabazza, E. and Kobayashi, T., 2018. A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer. *Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics*, 26(7), pp.1031-1036.
80. Krawczyk, P., Kowalski, D., Ramlau, R., Kalinka-Warzocha, E., Winiarczyk, K., Stencel, K., Powrózek, T., Reszka, K., Wojas-Krawczyk, K., Bryl, M., Wójcik-Superczyńska, M., Głogowski, M., Barinow-Wojewódzki, A., Milanowski, J. and Krzakowski, M., 2017. Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations. *Oncology Letters*, 13(6), pp.4433-4444.
81. FF Taufik, AD Susanto, E Simarmata, Faisal H, Jusuf A. Faktor risiko kanker paru. Dalam: Jusuf A, ed. *Seri Buku Ajar Onkologi Toraks : dasar - dasar diagnosis kanker paru*. Jakarta: Universitas Indonesia Press; 2017. h.11-23.
82. Sembiring R, Hidajat H, Jusuf A, S J. Klasifikasi Histologis Kanker Paru. Dalam: Jusuf A, ed. *Seri Buku Ajar Onkologi Toraks : dasar - dasar diagnosis kanker paru*. Jakarta: Universitas Indonesia Press; 2017. h.89 – 101.
83. Han B, Tjulandin S, Hagiwara K, Normanno N, Wulandari L, Laktionov K, et al. EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study. *Lung Cancer*. 2017;113:37 - 44.
84. Fatmawati F, Wulandari L. Profil pasien kanker paru jenis karsinoma bukan sel kecil yang mendapatkan terapi inhibitor tirosin kinase sebagai terapi lini pertama di

RSUD Dr Soetomo. Karya Akhir: Departemen Pulmonologi dan Ilmu Kedokteran Respirasi FK Unair, 2016

85. Sequist LV LT. EGFR Tyrosine Kinase Inhibitors in Lung Cancer : An Evolving Story. *Annual Review of Medicine* . 2008;59:429 - 42.
86. Herbst RS, Heymach JV, Lippman S. Molecular origins of lung cancer : lung cancer. *The New England Journal of Medicine*. 2008;359:1367 - 80.
87. Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. *Lung Cancer*. 2011;71:249-57.
88. Yang SC, Lin CC, Lai WW, Chang SM, Hwang JS, Su WC, et al. Dynamic changes in quality of life after three first - line therapies for EGFR mutation - positive advanced non small cell lung cancer. *Therapeutic Advances in Medical Oncology*. 2018;10:1 - 11.
89. Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C et al. Comparison of gefitinib, erlotinib and afatinib in non- small cell lung cancer: A meta- analysis. *International Journal of Cancer*. 2017;140(12):2805-2819.